MA Johnson

1.9k citations

75 papers · 2.3k · 1 hit paper · h-index 26

Impact in

Infectious Diseases top 1%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Tuberculosis Research and Epidemiology
Virology top 5%
- HIV Research and Treatment

Papers in

Infectious Diseases 55
- HIV/AIDS Research and Interventions 31
- HIV/AIDS drug development and treatment 23
- Tuberculosis Research and Epidemiology 5
Virology 15
- HIV Research and Treatment 15

Co-authors: Simon M. Barry (4 shared papers)Marc C.I. Lipman (10 shared papers)Sara Madge (8 shared papers)Mike S Youle (11 shared papers)George Janossy (2 shared papers)Caroline Anne Sabin (12 shared papers)Colette J Smith (14 shared papers)Sebastian B Lucas (3 shared papers)
Journals: HIV Medicine (28 papers)Antiviral Therapy (4 papers)European Respiratory Journal (3 papers)The Lancet HIV (2 papers)The Lancet (1 paper)
Partner nations: United Kingdom United States Denmark

In The Last Decade

MA Johnson

74 papers receiving 2.2k citations

MA Johnson's Hit Papers

align trajectories log scale

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study 2004 · 573 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2004 The Lancet

Peers

Countries citing papers authored by MA Johnson

Since Specialization

Citations

This map shows the geographic impact of MA Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MA Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MA Johnson more than expected).

Fields of papers citing papers by MA Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MA Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MA Johnson. The network helps show where MA Johnson may publish in the future.

Co-authors

The 25 scholars most cited alongside MA Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with MA Johnson Line = papers co-authored together MA Johnson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study The Lancet ·Frank van Leth, Praphan Phanuphak, Kiat Ruxrungtham, Ezio Baraldi, Sheila D. Miller, Brian Gazzard, Pedro Enrique Cahn, Lalloo Ug Hit paper breakdown →	2004	573
2	Tenofovir‐associated renal and bone toxicity HIV Medicine ·Andrew M. Hall, Ian Williams, Sara Madge, Andrew J Copas, Devaki R. Nair, Simon Edwards, MA Johnson, John O. Connolly +1 other	2009	242
3	British HIV Association guidelines for the treatment of TB/HIV coinfection 2011 HIV Medicine ·A L Pozniak, KM Coyne, Robert T. Miller, Marc C.I. Lipman, A.R. Freedman, Lawrence Peter Ormerod, MA Johnson, Simon Collins	2011	99
4	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial The Lancet HIV ·Chloe M. Orkin, Jean‐Michel Molina, Eugènia Negredo, José Ramón Arribas, Joseph Gathe, Joseph J. Eron, Erika Van Landuyt, Erkki Lathouwers	2017	82
5	Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease HIV Medicine ·PA. Fox, SE Barton, N. D. Francis, Mike S Youle, D.C. Henderson, Deenan Pillay, MA Johnson, Louise A. Fearfield	1999	77
6	Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV‐infected subjects HIV Medicine ·Simon M. Barry, Marc C.I. Lipman, A. Deery, MA Johnson, George Janossy	2002	71
7	Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited Bone Marrow Transplantation ·Simon M. Barry, MA Johnson, George Janossy	2000	64
8	Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS Pure Amsterdam UMC ·DW Boyer, S. J. Cowen, Ronald P. Danis, James G. Diamond, R. H. Fish, Debra Anne Goldstein, G. J. Jaffe, Jacob Paul Lalezari	2002	60
9	Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population HIV Medicine ·Tabitha W. Mahungu, Colette J Smith, Deirdre Egan, Mike S Youle, MA Johnson, Saye Khoo, DJ Back, Andrew Owen +1 other	2009	59
10	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy Antiviral Therapy ·Alessandro Cozzi-Lepri, Lı́dia Ruiz, Clive Loveday, Andrew N. Phillips, Bonaventura Clotet, PETER C. REISS, Bruno Ledergerber, Christian Holkmann	2005	57
11	Global HIV ‐1 transmitted drug resistance in the INSIGHT S trategic T iming of A nti R etroviral T reatment ( START ) trial HIV Medicine ·JD Baxter, David Dunn, Ellen White, Shweta Sharma, Anna María Geretti, Michael J. Kozal, MA Johnson, Simone Jacoby	2015	54
12	Changes in hospital admissions across Europe: 1995–2003. Results from the EuroSIDA study HIV Medicine ·Amanda Mocroft, Antonella d’Arminio Monforte, Ole Kirk, MA Johnson, Nina Friis‐Møller, Dénes Bánhegyi, Anders Blaxhult, F. M. Mulcahy	2004	50
13	BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005 HIV Medicine ·Al Pozniak, Robert T. Miller, Marc C.I. Lipman, AR Freedman, Lawrence Peter Ormerod, MA Johnson, Simon Collins, Sebastian B Lucas	2005	50
14	Cardiovascular disease risk factors and antiretroviral therapy in an HIV‐positive UK population HIV Medicine ·Colette J Smith, Caroline Anne Sabin, Ergün Barş Kaya, MA Johnson, Marc C.I. Lipman +1 other	2004	41
15	Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretrovial therapy era: relationships with gender* HIV Medicine ·Sapna S Shah, Colette J Smith, Fiona C. Lampe, Mike S Youle, MA Johnson, Andrew N. Phillips, Caroline Anne Sabin	2007	40
16	No association between HIV disease and its treatment and thyroid function HIV Medicine ·Sara Madge, Colette J Smith, Fiona C. Lampe, M Thomas, MA Johnson, Mike S Youle, Mark P. J. Vanderpump	2007	40
17	Response to Antiretroviral Therapy among Patients Exposed to Three Classes of Antiretrovirals: Results from the Eurosida Study Antiviral Therapy ·Andrew N. Phillips, Nina Friis‐Møller, Robert Colebunders, Margaret A. Johnson, Bernard J. Hirschel, Thierry Saint-Marc, Thérèse Staub, Bonaventura Clotet	2002	38
18	National review of deaths among HIV-infected adults Clinical Medicine ·Sebastian B Lucas, Hilary Curtis, MA Johnson	2008	38
19	Age, time living with diagnosed HIV infection, and self‐rated health HIV Medicine ·Jennifer McGowan, Lorraine Sherr, Alison J. Rodger, Martin Fisher, Alec H. Miners, Jane Anderson, MA Johnson, Jonathan Elford	2016	37
20	An audit of antiretroviral treatment use in HIV‐infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use HIV Medicine ·Caroline Anne Sabin, Fiona C. Lampe, Clinton Chaloner, Sara Madge, Marc C.I. Lipman, Mike S Youle, Andrew N. Phillips, MA Johnson	2003	33

About MA Johnson

MA Johnson is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Epidemiology and Pulmonary and Respiratory Medicine, having authored 75 papers that have together received 2.3k indexed citations. Recurring topics across this work include HIV/AIDS Research and Interventions (31 papers), HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (15 papers), HIV-related health complications and treatments (7 papers), Tuberculosis Research and Epidemiology (5 papers), Cytomegalovirus and herpesvirus research (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers) and Pneumocystis jirovecii pneumonia detection and treatment (2 papers). The work is most often cited by research in Infectious Diseases (1.5k citations), Virology (170 citations), Emergency Medicine (257 citations), Pharmacology (107 citations) and Epidemiology (268 citations). MA Johnson has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include Simon M. Barry, Marc C.I. Lipman, Sara Madge, Mike S Youle, George Janossy, Caroline Anne Sabin, Colette J Smith, Sebastian B Lucas, John O. Connolly and Ian Williams. Their work appears in journals such as HIV Medicine, Antiviral Therapy, European Respiratory Journal, The Lancet HIV and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

MA Johnson

Impact in

Papers in i

In The Last Decade

MA Johnson

MA Johnson's Hit Papers

Peers

Countries citing papers authored by MA Johnson

Fields of papers citing papers by MA Johnson

All Works

About MA Johnson

Explore authors with similar magnitude of impact

Papers in